MFS
CTMX icon

Mirabella Financial Services’s CytomX Therapeutics CTMX Stock Holding History

Mirabella Financial Services’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,400
Closed -$84K – 508
2022
Q1 		$84K Buy
+31,400
New +$121K 0.01% 441

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mirabella Financial Services's CTMX Position: Q2 2022 in Review

Mirabella Financial Services sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 31,400 shares — an estimated $84K sold.

Mirabella Financial Services first reported a position in CTMX in Q1 2022 and held it in 1 quarter. The position peaked at $84K in Q1 2022. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Mirabella Financial Services reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mirabella Financial Services sold 31,400 CytomX Therapeutics shares in Q2 2022, an estimated $84K.
  • Mirabella Financial Services first reported a position in CytomX Therapeutics in Q1 2022 and held it in 1 quarter.
  • Mirabella Financial Services's CytomX Therapeutics position peaked at $84K in Q1 2022.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Mirabella Financial Services's 13F filing for Q2 2022, filed 12 Aug 2022.